miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6.
about
Implications of miR cluster 143/145 as universal anti-oncomiRs and their dysregulation during tumorigenesisImpact of Nutrition on Non-Coding RNA Epigenetics in Breast and Gynecological CancerDNA methylation changes in epithelial ovarian cancer histotypes.FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancerMicroRNA-22 suppresses the growth, migration and invasion of colorectal cancer cells through a Sp1 negative feedback loop.HDAC 1/4-mediated silencing of microRNA-200b promotes chemoresistance in human lung adenocarcinoma cells.Low miR-145 silenced by DNA methylation promotes NSCLC cell proliferation, migration and invasion by targeting mucin 1.MicroRNA-186 induces sensitivity of ovarian cancer cells to paclitaxel and cisplatin by targeting ABCB1MicroRNA Pharmacoepigenetics: Posttranscriptional Regulation Mechanisms behind Variable Drug Disposition and Strategy to Develop More Effective TherapyA novel paclitaxel-loaded poly(d,l-lactide-co-glycolide)-Tween 80 copolymer nanoparticle overcoming multidrug resistance for lung cancer treatment.miR-217 and CAGE form feedback loop and regulates the response to anti-cancer drugs through EGFR and HER2.MicroRNA-137 inhibits tumor growth and sensitizes chemosensitivity to paclitaxel and cisplatin in lung cancerMiR-124 inhibits the migration and invasion of human hepatocellular carcinoma cells by suppressing integrin αV expression.Epigenetic mechanisms and therapeutic targets of chemotherapy resistance in epithelial ovarian cancer.Influence of microRNAs and Long Non-Coding RNAs in Cancer Chemoresistance.MicroRNAs and cancer resistance: A new molecular plot.MicroRNA-149 targets specificity protein 1 to suppress human tongue squamous cell carcinoma cell proliferation and motility.The Role of MicroRNAs in Resistance to Current Pancreatic Cancer Treatment: Translational Studies and Basic Protocols for Extraction and PCR Analysis.MicroRNA-218 inhibits tumor growth and increases chemosensitivity to CDDP treatment by targeting BCAT1 in prostate cancer.Hurdles in selection process of nanodelivery systems for multidrug-resistant cancer.MicroRNA-9 promotes tumorigenesis and mediates sensitivity to cisplatin in primary epithelial ovarian cancer cells.MiR-197 induces Taxol resistance in human ovarian cancer cells by regulating NLK.miR-145 inhibits invasion and metastasis by directly targeting Smad3 in nasopharyngeal cancer.MiR-145 inhibits osteosarcoma cells proliferation and invasion by targeting ROCK1.MicroRNAs in gynecological cancers: Small molecules with big implications.MicroRNA: A novel target of curcumin in cancer therapy.Updates and current challenges in microRNA research for personalized medicine in ovarian cancer.The expression of CDK1 is associated with proliferation and can be a prognostic factor in epithelial ovarian cancer.miR-495 sensitizes MDR cancer cells to the combination of doxorubicin and taxol by inhibiting MDR1 expression.miR-145-5p Suppresses Tumor Cell Migration, Invasion and Epithelial to Mesenchymal Transition by Regulating the Sp1/NF-κB Signaling Pathway in Esophageal Squamous Cell Carcinoma.Demethylation of the MIR145 promoter suppresses migration and invasion in breast cancer.Acquisition cancer stemness, mesenchymal transdifferentiation, and chemoresistance properties by chronic exposure of oral epithelial cells to arecoline.The Different Mechanisms of Cancer Drug Resistance: A Brief Review.A Peptide Nucleic Acid against MicroRNA miR-145-5p Enhances the Expression of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) in Calu-3 Cells.miRNA expression profiling in formalin-fixed paraffin-embedded endometriosis and ovarian cancer samples.Molecular mechanisms of drug resistance in ovarian cancer.The Network of Non-coding RNAs in Cancer Drug Resistance
P2860
Q26783563-6B91F63F-3C78-451B-9D32-00DE04EB5299Q27016123-7E40DDEA-D33E-44F7-A2A5-A2A08D3F324CQ27690722-30455C2E-C807-4676-BE07-92AD7FE09D58Q28075540-CD6FC8ED-7C65-411A-84CF-0E8DF27CBFFCQ33829470-E27724D8-6BF6-49D9-A95B-A16001CA1686Q33917640-0E1D9B46-7C77-4151-B5BC-BC1CD9E0C7F3Q36213360-BCDD87CA-DE57-4148-8F7F-27C8009107A7Q36341067-08D554E3-A085-4910-84F3-54D0C94EF810Q36618667-A4172738-FDDF-4B8D-9240-71DF717F1F53Q36951434-8511AC57-B0BC-44DB-AAD2-0D78D8CC0D69Q36962950-777C24DF-8271-4043-877C-240A37BCEB24Q37190423-1B6967C6-AAB8-419F-BC96-5821E7C657A2Q37589647-69D8F1A4-9F6D-4379-9872-C01416D11A4AQ38544386-0F4BCF1D-7DC6-477F-9DED-41D3128D6D1EQ38546133-2A1041DB-B392-4230-9A2B-2B1917006FAFQ38732712-9F3F3DB7-BC9A-4078-B99E-CFCEE0464949Q38737855-C1CCBB63-380A-4BA1-8AF0-4DA23A4C591CQ38748123-5F953913-1EB8-403E-BF2B-033DBBC04FA6Q38774889-4A61069B-553B-4F8A-B4D4-39EC369E67EAQ38818166-6D52A2AB-467B-41DF-A653-96CA68C8175DQ38890397-A05D10C4-EBB5-4FE9-8627-1F743DC11AF7Q38891975-093F6C8E-4DEB-43C2-AA44-6F2A515DA99BQ38921152-22862D20-D453-4E23-B51E-E3D25D7BD9A3Q38997887-09412998-BA96-4F4C-AE54-D76A1F77ED2BQ39333266-8150AD70-3125-4378-8D1A-9709213F3069Q39375777-90AAC96C-343E-45FB-B78B-9DB7C360593FQ39391417-B1652E0E-260F-4C23-B04A-1254F43A013AQ41016807-C1294BF5-DED2-425B-B167-EA86AE25CB87Q41520257-65E48347-3F10-47F4-BACA-5F84D61CFD49Q41661371-284FB929-5C4B-4F25-A02B-444090ECABDEQ41967527-56715184-ACC4-44A1-9679-33A799BE4191Q42315529-23C76D34-48C8-4EA3-81D7-91E3BCD53726Q42658274-50ED4516-8D87-4971-B41B-81C3DE896672Q47246071-59E57380-5E58-4A9C-A74C-48291BCE7C3EQ48000348-6570AA1C-F155-45B1-B7D1-884D65DD2B5EQ48274587-92D932C8-AB05-4796-B0DE-A812C54ADA6CQ58694197-99B3CE59-AB56-4739-ACB8-26D3173C9EF6
P2860
miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6.
@en
miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6.
@nl
type
label
miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6.
@en
miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6.
@nl
prefLabel
miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6.
@en
miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6.
@nl
P2093
P2860
P356
P1476
miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6.
@en
P2093
Chanjuan Xie
Huiling Shen
Xiaolan Zhu
Xinming Yin
P2860
P304
P356
10.1002/IJC.28774
P577
2014-04-28T00:00:00Z